Skip to main content
NASDAQ:GANX

Gain Therapeutics News Headlines

$9.79
+0.79 (+8.78 %)
(As of 05/14/2021 12:49 PM ET)
Add
Compare
Today's Range
$9.37
$9.79
50-Day Range
$9.78
$15.80
52-Week Range
$8.75
$17.93
Volume157 shs
Average Volume104,890 shs
Market Capitalization$116.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Gain Therapeutics (NASDAQ GANX) News Headlines Today

SourceHeadline
Gain Therapeutics (NASDAQ:GANX)  Shares Down 2.2% Gain Therapeutics (NASDAQ:GANX) Shares Down 2.2%
americanbankingnews.com - May 12 at 12:40 AM
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World CongressGain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress
finance.yahoo.com - May 3 at 8:37 AM
Gain Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience ConferenceGain Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference
finance.yahoo.com - April 27 at 5:08 PM
Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World CongressGain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress
finance.yahoo.com - April 22 at 12:36 PM
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis PharmaceuticalsGain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
finance.yahoo.com - April 20 at 8:14 AM
Gain Therapeutics, Inc.s (NASDAQ:GANX) Quiet Period Will Expire  on April 27thGain Therapeutics, Inc.'s (NASDAQ:GANX) Quiet Period Will Expire on April 27th
americanbankingnews.com - April 20 at 1:12 AM
Gain Therapeutics (NASDAQ:GANX) Earns Outperform Rating from Analysts at OppenheimerGain Therapeutics (NASDAQ:GANX) Earns Outperform Rating from Analysts at Oppenheimer
americanbankingnews.com - April 19 at 10:46 AM
Gain Therapeutics (NASDAQ:GANX) Coverage Initiated by Analysts at BTIG ResearchGain Therapeutics (NASDAQ:GANX) Coverage Initiated by Analysts at BTIG Research
americanbankingnews.com - April 19 at 8:46 AM
Why Gain Therapeuticss Stock is Up During Todays SessionWhy Gain Therapeutics's Stock is Up During Today's Session
msn.com - April 12 at 12:54 PM
Gain Therapeutics IncGain Therapeutics Inc
reuters.com - March 31 at 11:49 PM
Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional SharesGain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares
finance.yahoo.com - March 31 at 8:40 AM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.